> ## Content Index
> Fetch the complete content index at: https://www.elenapintea.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# From the pharmacy counter to Swissmedic: how a suspected ADR gets reported
- URL: https://www.elenapintea.com/from-the-pharmacy-counter-to-swissmedic-how-a-suspected-adr-gets-reported/
- Published: 2026-10-14T16:12:39.000Z
- Updated: 2026-11-19T16:24:25.000Z
- Description: Pharmacovigilance does not start in a safety database. It starts when a patient says, "Since I started these tablets, something isn't right." What happens next determines whether that observation becomes useful safety data or is lost.
- Author: Elena Pintea
- Tags: Adverse Drug Reaction Reporting

Pharmacovigilance does not start in a safety database. It starts when a patient says, "Since I started these tablets, something isn't right." What happens next determines whether that observation becomes useful safety data or is lost.

As a pharmacist in Swiss community pharmacies, at Amavita in Bülach and now at Coop Vitality in Feuerthalen, identifying and escalating suspected adverse drug reactions (ADRs) is part of my daily work. This article walks through the process step by step.

### The legal basis: a duty, not a favour

In Switzerland, the Therapeutic Products Act (HMG) obliges healthcare professionals (Therapeutic Products Act \[TPA\], 2000, Art. 59) who prescribe, dispense or administer medicines to report suspected ADRs. The obligation covers serious reactions and reactions that are not yet known, meaning they are not described in the product information (Medicinal Products Ordinance \[VAM\], 2018).

Reports go to Swissmedic, the Swiss Agency for Therapeutic Products, through its electronic vigilance system, ElViS (Swissmedic, n.d.). Swissmedic works with regional pharmacovigilance centres at university hospitals to assess the reports it receives from healthcare professionals.

Reporting a *suspicion* is enough. A pharmacist does not need to prove that the medicine caused the reaction.

### Step 1: Recognise the signal in a conversation

Patients rarely use the words "adverse reaction". They mention a new rash, dizziness, swollen ankles, unusual tiredness or a change in mood.

The first skill is listening for timing. A symptom that began after a new medicine, a dose change or a switch to a generic deserves follow-up questions. So does a symptom that improved when the patient stopped the medicine.

### Step 2: Ask the right questions

A useful report depends on a few key facts, collected calmly and without leading the patient:

- **What happened?** The symptoms in the patient's own words, plus what the pharmacist observed.
- **When?** The start date of the medicine and the start date of the symptoms.
- **Which medicines?** The suspected product with dose and batch number if available, and all other medicines, including self-medication and herbal products.
- **What was done?** Whether the medicine was stopped or the dose reduced, and whether the symptoms improved (dechallenge) or returned on re-exposure (rechallenge; Edwards & Aronson, 2000).
- **How serious?** Whether the patient needed hospital treatment, had a life-threatening reaction or suffered lasting harm (International Council for Harmonisation \[ICH\], 1994).

### Step 3: Protect the patient first

Reporting never comes before patient care. If a reaction looks serious, the immediate priority is to refer the patient to a doctor or emergency services.

For less urgent cases, I contact the prescriber to discuss stopping or changing the treatment. I also check the patient's medication record for interactions or duplications that might explain the symptoms.

### Step 4: Document clearly

Good documentation makes the difference between a report that can be assessed and one that cannot. I record the facts in the patient's pharmacy file at the time of the conversation, not from memory later.

Personal data must be minimised. A report to Swissmedic needs enough information to identify a real patient, such as initials, age and sex, but not a full name or address (ICH, 2003).

### Step 5: Submit the report

The report is entered in ElViS, with a clear narrative describing the sequence of events. A good narrative answers the questions a reviewer will ask: what, when, which medicines, what was done and what the outcome was.

If important information is still missing, the report can be submitted first and followed up later. Speed matters for serious cases.

### Step 6: Follow up and close the loop

Pharmacovigilance is a cycle. Follow-up information, such as the patient's recovery or a doctor's diagnosis, can change the assessment of a case.

At team level, I also share relevant cases with colleagues so the whole pharmacy becomes better at recognising similar reactions. Supporting the lead pharmacist in maintaining quality and safety standards includes this kind of knowledge sharing.

### What happens after the report

Once in the system, a case is assessed for seriousness and causality. It can be combined with similar cases from Switzerland and, through international databases, from other countries (Lindquist, 2008).

A single report may look insignificant. Together, reports allow regulators and companies to detect safety signals, update product information and, when necessary, issue safety communications to healthcare professionals.

### Why this experience transfers to industry

Pharmaceutical companies have parallel obligations. Marketing authorisation holders must collect, assess and report adverse events to Swissmedic within defined timelines (VAM, 2018), and train their own staff and business partners to recognise and forward safety information.

The skills are the same ones I use at the counter: recognising a possible adverse event in an everyday conversation, collecting the minimum information quickly, documenting it accurately and escalating it in time. In industry, the volume is larger and the systems are more formal, but the logic does not change.

### Key takeaways

- Swiss healthcare professionals must report serious and previously unknown suspected ADRs to Swissmedic.
- A good report covers what happened, when, which medicines, what was done and the outcome.
- Patient care comes first; clear, timely documentation makes the report useful.

### References

Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. *The Lancet, 356*(9237), 1255–1259\. https://doi.org/10.1016/S0140-6736(00)02799-9

International Council for Harmonisation. (1994). *Clinical safety data management: Definitions and standards for expedited reporting E2A*. https://www.ich.org

International Council for Harmonisation. (2003). *Post-approval safety data management: Definitions and standards for expedited reporting E2D*. https://www.ich.org

Lindquist, M. (2008). VigiBase, the WHO global ICSR database system: Basic facts. *Drug Information Journal, 42*(5), 409–419.

Medicinal Products Ordinance \[VAM\] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch

Swissmedic. (n.d.). \[Pharmacovigilance and ElViS adverse reaction reporting pages\]. https://www.swissmedic.ch

Therapeutic Products Act \[TPA\] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch